# US 2012/0252019 A1 · Detection of Bladder Cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252019 A1
- Document ID: US20120252019A1
- Status: Published application
- Kind: A1
- Application number: 13/472,331
- Filed: 2012-05-15
- Published: 2012-10-04
- Earliest claimed: 2007-08-17
- Assignees: Predictive Biosciences, Inc.
- Inventors: Anthony P. Shuber; Cecilia A. Fernandez
- Web page: https://patentgrep.com/patent/US20120252019A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- G01N 2333/96494: Matrix metalloproteases, e. g. 3.4.24.7
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention generally relates to methods of screening for cancer. Methods of the invention involve identifying a threshold parameter of a protein and of two or more nucleic acids, where the threshold parameters are indicative of the absence of cancer, conducting an assay in a sample to determine a parameter of the two or more nucleic acids and a parameter of the protein, and identifying the sample as positive for cancer if the parameters of at least one of the nucleic acids and the protein present in the sample are greater than their respective threshold parameters. In certain aspects of the invention, the nucleic acids include FGFR3, TWIST1, and NID2. In certain aspects of the invention, the protein includes MMP2 or MMP9.

## Claims

### Claim 1

A method of screening for cancer, the method comprising:
identifying a threshold parameter of MMP2 or MMP9 protein and of two or more nucleic acids selected from the group consisting of FGFR3, TWIST1, and NID2, wherein said threshold parameters are indicative of the absence of cancer;
conducting an assay in a tissue or body fluid sample in order to determine a parameter of two or more nucleic acids selected from the group consisting of nucleic acid encoding FGFR3, TWIST1, and NID2;
determining a parameter of MMP2 or MMP9 protein in said sample;
identifying said sample as positive for cancer if the parameters of at least one of said nucleic acids and the parameter of said protein present in said sample are greater than their respective threshold parameters.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer is a bladder cancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein the sample is selected from urine or blood.

### Claim 4 (depends on 1)

The method of claim 1, wherein the nucleic acid is DNA or RNA.

### Claim 5 (depends on 1)

The method of claim 1, wherein the parameter comprises a methylation pattern in the one or more of said nucleic acids.

### Claim 6 (depends on 1)

The method of claim 1, wherein the parameter comprises a mutation in at least one of said nucleic acids.

### Claim 7 (depends on 6)

The method of claim 6, wherein said mutation is selected from a loss of heterozygosity, a single nucleotide polymorphism, a deletion, an insertion, a rearrangement, and a translocation.

### Claim 8 (depends on 1)

The method of claim 1, wherein the parameter comprises a level of protein expression of said protein.

### Claim 9 (depends on 1)

The method of claim 1, wherein the parameter comprises a level of gene expression of at least one of said nucleic acids.

### Claim 10 (depends on 1)

The method of claim 1, wherein said assay comprises sequencing said nucleic acid.

### Claim 11 (depends on 1)

The method of claim 1, wherein said conducting and determining steps comprise
obtaining a sample comprising two or more said nucleic acids and MMP-2 or MMP-9 protein;
introducing an aptamer that binds to MMP-2 or MMP-9 protein in the sample;
removing unbound aptamer; and
conducting a single assay, wherein the assay detects both said nucleic acids and said protein, the assay comprising: performing a sequencing reaction on the two or more said nucleic acid and the aptamer, thereby detecting the nucleic acid and the aptamer in the sample.

### Claim 12 (depends on 11)

The method of claim 11, wherein said assay is a single molecule assay.

### Claim 13 (depends on 12)

The method of claim 12, wherein said single molecule assay is an ion semiconductor sequencing assay.
